| REVOLUTION MEDICINES |
| USA |
| Gesundheit |
| US76155X1000 / A2PYWG |
| 42Z (Frankfurt) / RVMD (NASDAQ) |
| FRA:42Z, ETR:42Z, 42Z:GR, NASDAQ:RVMD |
| - |
| https://www.revmed.com/ |
|
Revolution Medicines is a late-stage clinical oncology company focused on developing targeted therapies for cancers driven by the RAS protein, one of the most common cancer drivers affecting approxima..
>Volltext.. |
| 16792.95 Mio. EUR |
| 15445.62 Mio. EUR |
| - |
| -1006.92 Mio. EUR |
| -977.12 Mio. EUR |
| -5.11 EUR |
| 368.93 Mio. EUR |
| 331.44 Mio. EUR |
| -775.39 Mio. EUR |
| 6.97 |
| - |
| -66.16% |
| - |
| - |
| - |
| REVOLUTION MEDICINES, REVOLUTION MED |
| 19.03.26 |
|